Zepbound tops Wegovy for weight loss in Eli Lilly study
1 day ago · Shares of Eli Lilly climbed Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug Zepbound helped patients shed more pounds than Wegovy from rival Novo Nordisk. Lilly said patients taking Zepbound lost about 20% of their weight on average compared to nearly 14% for Wegovy. The drugmaker also said more ...
Eli Lilly's Zepbound tops Wegovy in head-to-head weight loss trial
1 day ago · Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in the first large, head-to-head trial of the highly in ...
Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk…
1 day ago · Eli Lilly said its obesity drug Zepbound led to more weight loss than its main rival, Novo Nordisk's Wegovy, in the first head-to-head clinical trial on the two weekly injections. The findings ...
Eli Lilly’s Zepbound Beats Novo Nordisk’s Wegovy in First Head …
People taking Zepbound lost 20.2% of their body weight on average after 72 weeks of treatment in the Lilly-sponsored study, compared with a 13.7% loss for Wegovy patients, Lilly said Wednesday ...
Zepbound leads to more weight loss than Wegovy, Eli Lilly says
2 days ago · Wegovy, also made by Novo Nordisk and with the same active ingredient as Ozempic, and Eli Lilly's Zepbound, with the same active ingredient as Mounjaro, are FDA-approved for weight loss.
Zepbound leads to more weight loss than Wegovy, drugmaker Eli …
1 day ago · Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from drugmaker Eli Lilly.. In a head-to-head comparison of the two GLP-1 drugs ...
Eli Lilly's Zepbound Tops Novo Nordisk's Wegovy in
1 day ago · Patients taking Eli Lilly's Zepbound lost more weight on average than those on Novo Nordisk's Wegovy in a new clinical study. Zepbound patients lost an average 20% of their body weight compared ...
Zepbound tops Wegovy in head-to-head study of weight loss …
1 day ago · Eli Lilly weight loss drug beat Wegovy in a head-to-head clinical trial — 20.2% body weight loss on Zepbound compared to 13.7% on Novo Nordisk obesity drug.
Lilly’s Zepbound Beats Novo’s Wegovy in Head-to-Head Trial
1 day ago · Eli Lilly & Co. said its weight-loss drug Zepbound outperformed rival Novo Nordisk A/S’s Wegovy in the first head-to-head trial of the two blockbusters. In a study sponsored by Lilly, people ...
Eli Lilly's Zepbound Whomps Novo Nordisk's Wegovy In First …
1 day ago · Eli Lilly said Wednesday its obesity drug Zepbound spurred more weight loss than Novo Nordisk's Wegovy in the first-ever head-to-head study. ↑ X The Weight-Loss Drug Market Is Hot.
- Some results have been removed